trusted by 100+ Patients

RGCC Oncotrail

Advanced Diagnostic Tool for Early Cancer Detection and Monitoring

Treatment Intro

What is RGCC Oncotrail?

Oncotrail is an advanced test developed by RGCC for individuals with a confirmed cancer diagnosis. It identifies tumour-associated markers in the blood, offering insight into how the cancer is progressing and responding to treatment.

With its high level of precision and non-invasive nature, Oncotrail helps guide personalised decisions throughout the treatment journey and supports long-term monitoring to reduce the risk of recurrence.

Why Choose it

Why Choose RGCC Oncotrail?

RGCC Oncotrail is a specialised liquid biopsy test for patients with a confirmed cancer diagnosis, designed to monitor cancer progression, evaluate treatment response, and assess the risk of relapse. It offers a non-invasive, precise, and personalised approach to ongoing cancer care.
🧬

Cancer Progression Monitoring

Oncotrail tracks key tumour-associated markers in the blood, offering clinicians real-time insights into cancer behaviour and progression over time.
💉

Non-Invasive

Using only a blood sample, Oncotrail eliminates the need for surgical biopsies—making it safer, faster, and more comfortable for patients.
📊

Real-Time Monitoring

The test helps determine how well a patient is responding to current therapies, allowing for timely adjustments to improve treatment outcomes.
🧠

Personalized Cancer Care

Oncotrail provides data specific to your cancer type and circulating tumour cells (CTCs), helping healthcare providers tailor treatments based on your individual cancer profile.
🎯

Highly Sensitive and Accurate

With its advanced molecular detection methods, Oncotrail delivers highly sensitive results - even in patients with low tumour burden - making it a reliable tool for monitoring.
🔬

Multiple Cancer Specificity

Oncotrail is compatible with several cancer types, offering a versatile solution for patients undergoing treatment or follow-up care across different oncology pathways.

The Process

How Does RGCC Oncotrail Work?

Oncotrail utilizes cutting-edge molecular biology and immunology techniques to isolate and analyze circulating tumor cells (CTCs) from a blood sample. These cells shed from primary and metastatic tumors and are present in the bloodstream. By examining the genetic material and markers of these CTCs, Oncotrail can identify cancer at its very early stages and track its progression throughout treatment. The test provides insights into:
Book a consultation
01
Cancer Detection
Detects even minute amounts of circulating tumor cells that are often undetectable with traditional methods
02
Treatment Efficacy
Monitors the response of cancer cells to therapies, helping healthcare providers to adjust treatment protocols as needed.
03
Cancer Recurrence
Detects the recurrence of cancer long before symptoms appear or imaging results indicate.
04
Scientific Rigour and Evidence-Based Decisions
Every treatment component we recommend is guided by robust data from the Onconomics Plus test, ensuring a highly individualised approach based on the unique molecular characteristics of your cancer.

Perfect for

Is This Test Right for You?

Who Can Benefit from RGCC Oncotrail?
Patients Undergoing Cancer Treatment: Those currently receiving cancer treatment can use Oncotrail to monitor the effectiveness of therapies and adjust the treatment as needed.
Cancer Survivors: Oncotrail can detect recurrence in cancer survivors, allowing for early intervention and improving long-term survival rates.
Healthcare Providers: Oncotrail offers physicians a reliable, real-time tool to track cancer progression and therapy response, ensuring optimal patient care.

FAQs

01

What is RGCC Oncotrail and how does it work?

RGCC Oncotrail is an advanced test that detects circulating tumour cells (CTCs) in a blood sample. These CTCs are shed by existing primary or metastatic tumours into the bloodstream. By identifying and analysing these rare cells, the test helps monitor cancer progression, assess treatment response, and track potential recurrence throughout the cancer journey.

02

What types of cancer can RGCC Oncotrail detect or monitor?

Oncotrail is suitable for detecting and monitoring several epithelial cancers, including breast cancer, prostate cancer, lung cancer, and colorectal cancer. It is particularly valuable for metastatic patients and individuals with a confirmed diagnosis seeking better insights into tumor progression and treatment response.

03

How is this test different from traditional cancer screening methods?

Unlike conventional tissue biopsies or imaging used in cancer monitoring, RGCC Oncotrail requires only a simple blood sample. It is minimally invasive and highly sensitive, capable of detecting even small numbers of tumour cells, making it an ideal tool for tracking disease status and evaluating treatment effectiveness over time.

04

Who should consider taking the RGCC Oncotrail test?

This test is beneficial for cancer patients currently undergoing cancer treatment, breast cancer patients, survivors concerned about cancer recurrence, and high-risk individuals with a family history of cancer. It also supports healthcare professionals in tailoring personalised treatment protocols based on evolving cancer dynamics.

05

What exactly are circulating tumor cells (CTCs), and why are they important?

Circulating tumor cells are tumor cells that have detached from a primary tumor or metastatic site and entered the bloodstream. These captured cells can indicate the presence of early cancer, help predict cancer prognosis, and guide clinicians in evaluating the effectiveness of current cancer treatments.

06

Can RGCC Oncotrail detect early-stage cancers?

No. RGCC Oncotrail is not intended for the early detection or primary diagnosis of cancer. It is used in patients with a confirmed cancer diagnosis to monitor disease progression, evaluate how treatment is working, and support long-term management strategies.

07

What makes RGCC Oncotrail a reliable cancer diagnostic test?

The test uses advanced molecular techniques to isolate nucleated cells of epithelial origin, leveraging markers such as the epithelial cell adhesion molecule for precise identification. Fluorescence microscopy is employed to visualise and confirm the presence of CTC markers, including those found in epithelial tumor cells, stem cell markers, and other relevant indicators. While not a primary diagnostic test, it is a powerful adjunct for real-time clinical monitoring.

08

Is RGCC Oncotrail useful for tracking cancer metastasis?

Absolutely. By identifying CTCs and even ctc clusters, the test offers insights into the metastatic process. This supports early detection of brain metastasis, metastatic breast cancer, and spread to other organs like the liver (hepatocellular carcinoma), allowing for faster intervention and better-informed care.

09

How does RGCC Oncotrail support personalised cancer care?

The test provides molecular characterization of target cells, helping doctors understand the unique biology of a patient’s cancer. This enables more informed decisions about therapy, adjustment of treatment protocols, and monitoring of treatment effectiveness in real time, particularly in the context of complex tumor evolution.

10

What kind of sample is needed for the test, and is it painful?

Only a blood sample is required . The test analyses blood samples, including white blood cells, red blood cells, and immune cells, to isolate and study the relevant tumour cells for evaluation.

10

Where does RGCC Oncotrail fit into the cancer monitoring process?

After a confirmed cancer diagnosis - typically established through imaging or tissue biopsy - the focus shifts from early diagnosis to continuous monitoring and treatment planning. One of the most advanced tools available for this purpose is the RGCC Oncotrail test.

This test works by analysing peripheral blood for the presence of circulating tumour cells (CTCs), which are shed by the primary tumour or metastatic sites. These individual tumor cells, often of epithelial cancer cell origin, provide important insights into how the disease is evolving.

By using a simple blood test, Oncotrail enables precise treatment response monitoring without the need for repeated invasive procedures. It can help detect early signs of progression or relapse by identifying tumour-associated markers in the bloodstream, making it a powerful adjunct in managing cancer over time - especially for cancers where tracking tumor cell activity is critical to personalising care.